Daniel Watson joined BBOT in September 2024 as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC). Daniel is a seasoned pharmaceutical professional with more than 20 years of experience in small molecule research and development from early- to late-stage and through commercialization.

He previously served as Vice President, CMC, at Chinook Therapeutics Inc., a Novartis company (acquisition by Novartis in 2023) leading the small molecule portfolio pharmaceutical development, clinical, and commercial manufacturing. Most notably, he led the technical advancement for the development of atrasentan, an investigational oral endothelin A receptor through Phase III (ALIGN) studies in IgA nephropathy (IgAN). Daniel began his career in process chemistry at Bristol Myers Squibb and moved on to roles of increasing responsibilities at Array BioPharma Inc. (acquired by Pfizer), Cascadian Therapeutics, Inc. (formerly Oncothyreon Inc., subsequently part of Seagen) and Seagen (acquired by Pfizer) where he was instrumental in the development and execution of the strategy leading to the successful launch of TUKYSA^® (tucatinib), approved for the treatment of HER2-Positive Metastatic Breast Cancer and Unresectable or Metastatic Colorectal Cancer.

Daniel completed a postdoctoral fellowship at Colorado State University, holds a PhD in Synthetic Organic Chemistry from the University of Liverpool, UK, and a BSc in Chemistry from the University of Exeter, UK.